© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Rifamycin O belongs to a family of antibiotics that changed the fight against several tough bacterial infections. Researchers at Lepetit in Italy first isolated rifamycins from the fermentation broth of Streptomyces mediterranei in the late 1950s. The molecule emerged from the creative collaboration of chemists and microbiologists working to unravel new anti-tuberculosis drugs. Science then focused on pinpointing which component from the broth brought the greatest value. Rifamycin O emerged as a valuable intermediate, especially as a parent structure for widely used derivatives like rifampicin and rifabutin. This structural backbone offered a unique way to block bacterial RNA synthesis, leading to an overhaul in how medical practitioners tackled tuberculosis and leprosy. Its discovery emerged from a period where penicillins and tetracyclines were starting to meet the roadblocks of microbial resistance. That historical pressure made rifamycins an attractive solution for expanding the therapeutic arsenal.
Rifamycin O stands out in the rifamycin drug class for its role as both a research tool and a starting material for making more clinically relevant antibiotics. Although rarely used directly as a medicine, its value lies in extraction and modification. The molecule affords researchers an opportunity—by tweaking certain chemical groups, one obtains antibiotics with better penetration into bacterial cells and less toxicity in humans. Pharmaceutical companies rely on rifamycin O as a precursor in their manufacturing flow, often favoring it for predictable yields and ease of handling during chemical synthesis steps. Without this compound paving the way, a range of rifamycin-related antibiotics that save lives today would not make it to pharmacy shelves.
Chemists describe rifamycin O as a reddish-brown powder, sometimes showing small crystalline characteristics under the microscope. It dissolves well in organic solvents such as chloroform and methanol, but not nearly as well in water. The core ring structure features a span of seventeen atoms, known as an ansa chain, bridging key benzene rings. This unique architecture is what gives rifamycins their power: it latches onto bacterial RNA polymerase and jams up the machine that bacteria use to replicate genetic instructions. Its distinct molecular weight and spectral properties let laboratory staff quickly pick it out from a mixture, speeding up both quality control and subsequent chemical transformations. Chemical reactivity centers on the molecule's phenolic and naphthohydroquinone groups, which play a crucial role in later transformation steps.
Accurate, honest labeling protects patients down the line. Rifamycin O’s technical sheets usually spell out purity levels above 95%, with clear notations of trace impurities like unreacted fermentation byproducts or solvent residues. Pharmaceutical suppliers specify both melting point and storage conditions, recognizing that the compound decomposes if left above room temperature or in bright light. Quality assurance staff rely on HPLC and TLC methods to verify batch identity, often supported by spectral data from NMR and UV-Vis analysis. The product gets shipped in airtight, amber-glass vials to block out moisture and UV – a lesson learned over years of observing the compound’s sensitivity to environmental factors. Each batch carries a unique lot number, not only for inventory but also for traceability in case downstream products ever require recalls or additional testing.
Fermentation remains the heart of rifamycin O production, harnessing industrial-sized tanks filled with Streptomyces mediterranei or related rifamycin-producing strains. Controlled nutrient feeds and oxygen levels help the bacteria churn out a cocktail of rifamycins. Chemists extract the fermentation broth with solvents such as ethyl acetate, then further concentrate and purify rifamycin O using silica gel column chromatography. This removes related molecules and leaves a relatively pure product ready for further chemical modifications. The process balances yield, cost, and environmental considerations. Over the years, fermentation scientists have fine-tuned strains for maximum output, cut down on waste, and improved efficiency—helping lower the price and environmental impact of this raw material on which so much downstream antibiotic production depends.
Rifamycin O sets the stage for numerous semi-synthetic derivatives. Medicinal chemists turn to this molecule because its functional groups—especially at positions C-3 and C-4—take well to chemical modification. Hydrogenation, methylation, and acylation reactions allow fine-tuning, each change adjusting how the resulting antibiotic enters and acts inside bacterial cells. The transformation from rifamycin O to rifampicin, for example, requires a condensation reaction with a hydrazine reagent. Fine control over these reactions determines batch yield, cost, and even patentability. Companies often guard reaction conditions as trade secrets, since subtle tweaks can make a major difference in the downstream clinical properties. The chemistry speaks to broader pharmaceutical manufacturing themes: starting with a flexible, workable skeleton pays off when adapting to new resistance threats or regulatory requirements.
Through literature and industry catalogs, rifamycin O carries several aliases. Some references use the term “rifamycin O” directly; others cite its development code “LM-427.” Patent filings might detail the molecular structure or refer to it as part of the rifamycin B family. This patchwork of naming conventions can cause confusion for researchers or procurement staff, particularly in global markets where translation or local nomenclature rules apply. Manufacturers keen on transparency list all synonyms on regulatory filings, enabling clear communication through the supply chain and across international borders. Some vendors also brand the molecule with trade names linked to their own antibiotic portfolios, though these proprietary names rarely stick at the broader scientific level.
Working with rifamycin O calls for savvy laboratory practices and strict adherence to occupational health rules. While rifamycins display low acute toxicity, their powder form easily becomes airborne, posing inhalation risks. People handling the substance use protective gloves, dust masks, and safety glasses. Rooms stay ventilated and surfaces get wiped down often to keep exposure low. Laboratories store the material in dedicated chemical safes, kept dry and dark, away from incompatible acids or bases which could degrade the material. Disposal procedures emphasize environmental stewardship, with spent solvents and contaminated materials incinerated or treated for safe breakdown. Companies routinely review safety data, especially if manufacturing upgrades or regulatory changes demand new guidelines. These rules protect both workers and downstream patients who ultimately rely on uncontaminated, high-quality antibiotics.
Medicine depends on rifamycin O chiefly as a waystation to more advanced antibiotics. Without it, the world would not have drugs like rifampicin, a frontline therapy for tuberculosis and leprosy. Its role as a parent compound lets chemists customize antibiotics for specific challenges—whether attacking drug-resistant bacteria or easing formulation for vulnerable patient groups. Many scientists use rifamycin O in molecular research, modeling how modifications at the chemical level tweak bacterial killing power. Biomedical laboratories employ it in efforts to chart resistance pathways and predict bacterial evolution. While direct clinical use as an antibiotic remains limited, every batch of finished rifamycin-type medicine likely traces its roots to this key intermediate.
Antibiotic innovation moves quickly, spurred by the steady march of drug resistance. Rifamycin O sits at the center of much of this work. Laboratories routinely return to the molecule looking for new semi-synthetic derivatives: slightly modified structures that dodge bacterial resistance without harming patients. Research teams, including those I've worked with, combine medicinal chemistry, computational modeling, and rapid screening to hunt for next-generation antibiotics. Others look for greener, more sustainable ways to make rifamycin O, aiming to cut chemical waste or energy use. New biological fermentation methods have already raised output; ongoing R&D explores optimized microbial strains and enzyme-driven synthetic routes. Progress here not only brings hope to treating stubborn infections, it also assures that future generations will have tools at hand when older drugs lose their punch.
Understanding toxicity sits at the foundation of turning any raw molecule into a safe drug. Scientists working with rifamycin O conduct rigorous studies in cell cultures and animal models. Most findings confirm that rifamycin O itself carries more risk than its refined derivatives, which is part of why you rarely encounter it in a hospital pharmacy. Toxicologists track how the molecule breaks down in the liver and how traces might build up in tissues. Some animal tests show potential impacts on the liver and red blood cells, issues that chemists work to address by modifying chemical groups or tweaking dosages in derivatives. Throughout my time organizing collaborative safety screenings, I saw firsthand how even tiny tweaks at the molecular level can shift toxicity profiles, underscoring why every new batch or modification comes with a new round of tests.
The coming years look to challenge and expand rifamycin O’s legacy. As bacterial resistance pushes older antibiotics aside, researchers invest fresh energy into molecular variants that start from the sturdy rifamycin O skeleton. The groundwork already in place eases the path for new candidates—scientists don't start from scratch, but rather build on decades of experience. Future work may shift fermentative production toward strains that secrete more and cleaner product, cutting downstream purification burdens. Environmental awareness pushes process engineers to design closed-loop, waste-minimizing synthesis pipelines. Policy shifts might encourage wider data sharing on intermediate toxicity and encourage international harmonization of labeling and safety standards. On the scientific frontier, a new generation of researchers looks ready to tinker with the molecule toward better, safer drugs that can withstand the pressures of a rapidly evolving microbial world. Investing in basic research, collaboration between companies and public health agencies, and open access to data on safety will matter more as the global community faces antibiotic resistance head-on.
Rifamycin O stands as an antibiotic trusted by doctors to tackle tough bacterial infections, especially those that resist common antibiotics. This drug steps in for people fighting diseases like tuberculosis and certain kinds of staph infections. When I think of antibiotics, too many times people treat them as a backup plan — something to reach for only after other options fail, or, sometimes, something to misuse. That laid-back attitude comes partly from how easy it once seemed to get antibiotics, but diseases like tuberculosis remind everyone just how serious bacterial infections can turn.
Rifamycin O gets its power from its ability to block an enzyme that bacteria need to make RNA. No RNA, no new proteins, and that leads straight to dead bacteria. The magic happens inside the bacteria, with the drug stopping the infection from spreading. This isn’t just about treating symptoms. Killing the infection at its root means less risk the bacteria bounce back stronger or find a way around the drug.
Doctors reach for rifamycin O especially with tuberculosis, a disease that’s been making a quiet comeback in unexpected places. Its stubborn resistance grows every year. Rifamycin O helps by reaching inside cells where the bacteria hide, giving a chance at a real cure. Over the years, scientists saw that drugs like this remain one of the few reliable shields against deadly outbreaks.
Problems start brewing when people treat antibiotics like candy. Maybe someone skips doses or stops early because they feel better. That’s how resistant strains show up. An issue like antibiotic resistance grows bigger than one person’s treatment: it inches closer to the day when these drugs just don’t work. The World Health Organization calls antibiotic resistance one of the top threats to global health, and it’s not just scare tactics. Each year, drug-resistant infections cause hundreds of thousands of deaths all over the world. Rifamycin O isn’t immune to this trend. If people keep misusing antibiotics, even powerful options like this might fail when people really need them.
Real solutions start in regular clinics and homes. People listening to their doctors, finishing courses of treatment, not demanding antibiotics for every sniffle. Hospitals can run stewardship programs, making sure the right drug matches the right infection and minimizing unnecessary prescriptions. Pharmacists add another layer of caution, double-checking that prescriptions make sense for what someone faces.
On the research side, scientists keep watching for signs that bacteria are learning new tricks. When resistance shows up, new studies and combinations become urgent. Drug development always costs millions and takes years. Pushing for smarter use helps buy time for new options to get through testing and reach patients who need them most.
People count on drugs like rifamycin O for hope and real change in dangerous infections. Families don’t forget how quickly diseases like TB can upend lives. Each time antibiotics get used wisely, it helps make sure this option remains for those in real trouble. That responsibility rests on everyone: patients, doctors, families and researchers. Every dose counts, not just for one person, but for future generations hoping to face fewer hurdles in the fight against bacterial disease.
Rifamycin O stands out in the fight against bacterial infections, especially those caused by Gram-positive bacteria. Its roots trace back to natural soil actinomycetes, and today, it forms part of the toolkit for specialists treating serious infections. I’ve talked with infectious disease doctors who often rely on antibiotics like this when faced with persistent bacteria that resist common medicine.
Getting the administration right means life or death for some patients. I watched teams in hospitals debate whether to use oral or intravenous delivery, and Rifamycin O rarely comes up as a standard prescription for routine infections—it’s reserved for more specific problems, usually when simpler drugs fail or resistance rears its head.
Healthcare teams don’t guess doses. They match the bacteria, the patient’s health, blood levels, and liver function before starting. Mistakes bring consequences. Overdosing can lead to liver stress, something I’ve seen more than once, while skipping doses opens the door for resistant bacteria to take hold. With Rifamycin O, nurses check kidney and liver function, especially in older adults or those with preexisting issues. These safety checks stand as a testament to how high the stakes run.
Doctors often consider both oral and intravenous routes. Rifamycin O isn’t a ‘one-pill-fits-all’ solution. Some derivatives work better in pill form, but the original molecule often needs delivery by injection. The doctors I know favor injections when dealing with advanced tuberculosis or stubborn staph infections, where reliable absorption counts.
If a patient can take pills, and the infection site allows, oral therapy gives more flexibility. It lowers costs and lets people recover at home, away from the stress of long hospital stays. For gut infections, the oral route sometimes works better since the medicine acts at the infection’s location.
IV forms matter in acute infections, where time and concentration count most. The intravenous route gets medicine straight to the bloodstream, making sure none gets lost in digestion. In cases of sepsis or rapidly spreading infection, this speed makes all the difference.
Anyone starting Rifamycin O should have medical supervision. Drug interactions lurk everywhere—some common ones include blood thinners and diabetes medications, since Rifamycin can crank up or slow down the body’s drug processing factories in the liver. It’s not rare for patients to end up with fluctuating insulin or warfarin levels, an issue raised weekly in most large clinics.
Monitoring for side effects takes place almost every day in busy wards. Rashes, stomach upset, or even rare allergic reactions can pop up. Some people see orange or red urine, a harmless but alarming effect that nurses should warn people about, since I’ve seen more than one patient panic when it occurred.
We lose ground to resistant microbes every year. Every time people neglect doctor instructions or skip doses, it arms bacteria with new defenses. Digital pill boxes that track doses and send reminders could help patients stick to regimens. More public education about antibiotics’ risks matters as well—many still think antibiotics are cure-alls, which just isn’t true.
Rifamycin O has earned respect from the people using it at the bedside. Its power comes with responsibility. The best results show up where teams work together—doctors, nurses, pharmacists, and families all focused on one thing: giving the right drug, the right way, to the right person.
Rifamycin O stands out as a member of the rifamycin family, mostly used for its antibiotic qualities. Doctors often prescribe it to tackle infections caused by bacteria, and it’s not unusual to see it used for specific gastrointestinal conditions. Anyone taking this medication deserves straightforward information about what could happen once those pills or drops start doing their job.
Taking Rifamycin O doesn’t guarantee everyone will notice side effects, but a few tend to pop up more often. Most commonly, people talk about stomach discomfort. Folks might deal with cramps, nausea, or even an urgent run to the bathroom. These aren’t just numbers from studies; real patients often bring up these invasive routines during their daily lives. Working as a volunteer in a health clinic, I’ve seen people cut short a course of antibiotics since trips to the restroom made work and social life uncomfortable.
Rifamycin O, like other drugs in its class, has a reputation for causing changes in the color of bodily fluids. Some people notice reddish or orange shades in their urine or even tears. This throws folks off, sometimes causing unnecessary worry. I once reassured a neighbor after they called me late at night, alarmed by their surprising toilet visit after starting antibiotics. Still, the discoloration itself rarely brings further health problems—just a good reminder to ask questions instead of panicking.
Some folks talk about headaches or dizziness, and while the percentages look low in official literature, it only takes one afternoon of thumping pain to realize how much it can affect a workday. Fatigue sometimes tags along, which feels more like a slow-down than outright illness but deserves mention so people aren’t left wondering if something more serious is afoot.
Allergic reactions sit on the rare side, but ignoring the signs can grow serious quickly. Hives or trouble breathing stand out as red flags. Anyone who notices swelling of lips or face should get medical help fast. Professionals always talk about these possibilities before starting a new medicine, and ignoring “just a mild allergy” can turn a simple episode into a hospital stay. I once saw a patient’s mild rash grow into something worse because they waited before phoning their doctor.
Antibiotics can mess with the gut, and Rifamycin O joins this club. The healthy bacteria in the digestive tract keep things smooth, but a course of antibiotics can knock that balance off. Occasionally, this leads to problems like diarrhea that could turn into a bigger challenge, especially if it sticks around or comes with a fever. Medical researchers keep an eye on Clostridioides difficile infection, which shows up more often in those who take antibiotics. Staying in touch with a doctor when diarrhea won’t quit helps catch these rare cases early.
A clear path forward means open conversation between patients and doctors. Sharing every symptom, no matter how small, keeps things safe. Doctors must stress the importance of finishing the full course, not bailing because of a stomachache or a scary color in the toilet. People often benefit from tips like pairing the medicine with food or water to ease stomach complaints. Tracking symptoms with a notebook helps sort temporary annoyances from bigger worries.
No one wants to wade through side effects without guidance. Pharmacies, nurses, and patient handouts all play a role in building trust and making sure people act early if something feels off. Honest reporting and feedback help doctors refine their advice and watch for patterns that studies might miss.
Antibiotics sit at the center of many tough decisions in healthcare, especially with pregnancy or breastfeeding in the picture. Rifamycin O, a member of the rifamycin class, often enters discussions about treating bacterial infections. Many expectant or nursing mothers don’t just want to address symptoms—they need to know if what works for others could put their child at risk. Looking at this question through the lens of medical evidence and lived experience helps shine a light on why doctors think so hard before prescribing.
Most safety data about rifamycins centers around two other drugs in the group—rifampin and rifabutin—both of which doctors use for tuberculosis and related infections. These drugs cross the placenta and also show up in breastmilk. Researchers have found that, in pregnancy, rifamycins may slightly increase the risk of bleeding disorders in the newborn, especially if the mother receives the drug close to delivery. For that reason, many providers supplement with vitamin K during the last weeks of pregnancy if antibiotics from this class must be used.
Rifamycin O is different. It is mainly a topical or oral agent, so systemic absorption stays much lower than with oral rifampin. Fewer studies exist. Animal data for rifamycins suggest there is no clear link between standard doses and birth defects. This is good news, but it doesn’t erase the unknowns. Human studies almost always lag behind drug approvals, especially when pregnant or breastfeeding people are involved. Every case sits on a delicate balance of battling an infection quickly or worrying about effects no one has fully tracked over generations.
I’ve seen how doctors talk with patients who are pregnant or breastfeeding and worried about any drug. Most parents bring up every concern—the smallest “what if.” In the hospital, when infections start threatening the health of the mother, the baby, or both, quick choices matter. Doctors want good outcomes for everyone involved, but trusting a medication calls for more than hope. It calls for facts.
So far, organizations like the World Health Organization and U.S. CDC do not list Rifamycin O as the first pick during pregnancy. They stick with better-studied options, especially for infections that pose serious risks to both mother and child. If all safer drugs fail, or if an allergy appears, then a topical or poorly absorbed agent like Rifamycin O might step in. Medical teams look hard at the exact infection, weigh alternative treatments, and calculate whether the benefits of treating with Rifamycin O outweigh any unclear risk.
Nursing mothers want to avoid passing medication to their newborns through breastmilk if side effects remain unclear. Since only trace amounts of topical antibiotics usually pass into milk, doctors sometimes allow their use—but only if truly needed. For oral Rifamycin O, the risk stays low, but isn’t zero. In my experience, open communication and shared decision-making sit at the core of any solution. Doctors keep a close eye on the baby, watching for changes in feeding, sleep, or color. They stand ready to adjust course if anything shifts.
Staying up-to-date on medication safety means working with both current evidence and real-world experience. Medical teams tap into the latest studies, prioritize transparency, and make space for every question. Pregnant and breastfeeding women deserve care that blends science and respect for personal values. With antibiotics like Rifamycin O, a thoughtful and honest discussion goes further than any comfort from scientific jargon. The best care gives families confidence they are making the right call for both mother and child.
Rifamycin O comes from a family of antibiotics that medical professionals turn to for certain bacterial infections. Not many folks run into it during a routine doctor visit, but for people dealing with digestive issues or infections like traveler’s diarrhea, it pops up as a prescription. It targets bacteria in the gut and doesn’t get absorbed deeply into the bloodstream. That means its interaction profile may look different from other antibiotics.
Even if a medication mostly stays in the gut, that does not place it outside the web of drug interactions. Having worked with patients on a heap of different medications, I’ve seen how even “localized” drugs mess with the gut’s bacteria, and that can shift how the body processes other drugs. Rifamycin O shares a chemical backbone with other rifamycins, like rifampin, which have a reputation for sparking drug interactions, particularly with medicines processed by the liver.
The reason rifampin and relatives like Rifamycin O matter in this way has to do with enzymes called CYP450s. These enzymes live mostly in the liver and chomp through foreign substances, including medications. Rifamycins often kick these enzymes into a higher gear. That can drop levels of other drugs in the body, making those drugs work less well. Rifampin can weaken birth control pills, HIV medicines, blood thinners, and many others.
Rifamycin O stays mostly in the digestive tract because it isn’t absorbed well, so far fewer studies point to it causing these same kinds of enzyme shifts. Data shows risk is a lot lower, especially compared to rifampin. Still, because it is part of the same family, it makes sense to be cautious, especially for people already taking drugs with narrow windows for safety—think warfarin, antiepileptics, or transplant medicines.
Another angle comes from how antibiotics reshape the gut’s bacteria community. My own experience helping folks on long courses of antibiotics taught me to look out for changes in how the body absorbs or breaks down drugs. The gut microbiome helps manage how much and how fast some drugs drift into the bloodstream. Shaking up that balance can mean more or less drug working in the body than expected. For Rifamycin O, this risk matters mainly in people on dozens of pills, where even small changes can snowball.
Patients juggling multiple prescriptions should keep all health professionals in the loop when they get a new medication like Rifamycin O. Electronic health records, pill organizers, or even a simple list in a notebook can keep the details straight. Pharmacists should flag new prescriptions and run checks against allergy lists and ongoing drugs. Doctors can keep an eye on high-stakes medicines like blood thinners or anti-seizure drugs, watch for early warning signs, and check lab results if needed.
Doctors also should explain what symptoms might hint at trouble, like unusual bleeding, changes in mood, or out-of-the-blue allergic reactions. If it sounds like a small thing, remember: most drug interactions become a story of “what I noticed first” from the patient or their family, not from a test.
Rifamycin O generally comes with less baggage than some of its cousins, but no antibiotic travels entirely solo. With antibiotics we always need to weigh risks, communicate with the whole care team, and keep an eye out for changes—especially in people on many drugs or those with weakened immune systems. That way, no side effect catches anyone by surprise.
| Names | |
| Preferred IUPAC name | (7S,8R,9S,10E,12R,13S,14R,15E,17S,18S,19E,21S,22S,23E,25S,26S,27E,29S,30S,31E,33S,34S,35E)-2,4,8,14,18,22,26,30-octahydroxy-7,12,13,17,21,25,29,33-octamethyl-1,11,16,20,24,28,32-heptaoxabicyclo[29.3.1]pentatriaconta-10,15,19,23,27,31-hexaene-3,5,6-trione |
| Other names |
Rifaldazine Rifaldizin |
| Pronunciation | /raɪˈfæmɪsɪn oʊ/ |
| Identifiers | |
| CAS Number | 11013-92-4 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Rifamycin O**: ``` CC1=C(C(=O)C2=C(C=C(C3C(C2=O)C(C(C(C3O)O)O)(C)O)O)C(=C1O)C=CC(=O)CO)CO ``` |
| Beilstein Reference | 140883 |
| ChEBI | CHEBI:87070 |
| ChEMBL | CHEMBL507230 |
| ChemSpider | 21566937 |
| DrugBank | DB03311 |
| ECHA InfoCard | 100.080.608 |
| EC Number | 6.3.1.85 |
| Gmelin Reference | 85947 |
| KEGG | C08410 |
| MeSH | D012311 |
| PubChem CID | 70683565 |
| RTECS number | VV7780000 |
| UNII | O4F7952HWT |
| UN number | UN3249 |
| CompTox Dashboard (EPA) | DTXSID0021456 |
| Properties | |
| Chemical formula | C37H47NO12 |
| Molar mass | 835.938 g/mol |
| Appearance | Rifamycin O is a yellow to orange crystalline powder. |
| Odor | Odorless |
| Density | 1.7 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 1.92 |
| Acidity (pKa) | 7.1 |
| Basicity (pKb) | 13.16 |
| Refractive index (nD) | 1.712 |
| Dipole moment | 4.0992 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 665.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -482.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -7269 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | J04AB03 |
| Hazards | |
| Main hazards | Causes eye irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05, GHS07 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | Keep container tightly closed. Store in a dry place. Avoid breathing dust. Wear suitable protective clothing. |
| NFPA 704 (fire diamond) | NFPA 704: 2-1-0 |
| Flash point | > 87.6 °C |
| Lethal dose or concentration | Lethal dose or concentration: LD50 (rat, oral): >5,000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Rifamycin O: "2880 mg/kg (rat, oral) |
| NIOSH | RXC91349 |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | US$56.00 |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Rifampicin Rifabutin Rifapentine Rifalazil Rifamycin S Rifamycin SV 3-Formylrifamycin SV |
